Cover Image
市場調查報告書

主要已開發國家到2021年的多發性骨髓瘤 (MM) 治療藥市場:盛行率的增加、Revlimid的持續成功、新興補助治療促進成長

Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments

出版商 GBI Research 商品編碼 336892
出版日期 內容資訊 英文 119 Pages
訂單完成後即時交付
價格
Back to Top
主要已開發國家到2021年的多發性骨髓瘤 (MM) 治療藥市場:盛行率的增加、Revlimid的持續成功、新興補助治療促進成長 Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments
出版日期: 2015年07月01日 內容資訊: 英文 119 Pages
簡介

多發性骨髓瘤(MM),是特徵為骨髓中的漿細胞增生的血液學性惡性腫瘤。在多發性骨髓瘤 (MM) 開發平台上,分子類型和治療標的範圍遼闊包含267種產品。

本報告提供主要已開發國家的多發性骨髓瘤 (MM) 治療藥市場相關調查分析、市場概要、上市產品、開發中產品、市場預測、交易和策略性整合等相關的系統性資訊。

第1章 目錄

第2章 簡介

  • 疾病概要
  • 病因
  • 病理生理學
  • 症狀
  • 診斷與分類
  • 流行病學
  • 預後和分期
  • 治療的選項

第3章 上市產品

  • 概要
  • 免疫調節藥
  • 蛋白酶體抑制劑
  • 組蛋白去乙醯酶抑制劑
  • 化療
  • 比較有效性和安全性

第4章 開發中產品

  • 開發平台全體
  • 開發平台分析:各分子標的
  • 臨床試驗
    • 失敗率
    • 臨床試驗的規模
    • 期間
  • 競爭的臨床試驗的標準分析
  • 開發平台中有前途藥物的候補
  • 開發中產品的熱圖

第5章 市場預測

  • 地區市場
  • 全球市場
  • 北美
  • EU主要5個國家
  • 日本
  • 推動因素與阻礙

第6章 交易與策略性整合

  • 授權協議
  • 共同開發交易

第7章 附錄

圖表

目錄
Product Code: GBIHC365MR

Executive Summary

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000. The disease is considered incurable, although the past decade has seen significant improvements in therapy, driven by a greater understanding of pathophysiology. Many of the leading drugs in the market were approved over the past 10-15 years, and have improved median survival rates by about 50%.

The MM pipeline contains 267 products in active development, encompassing a range of molecule types and therapeutic targets. The innovation that has characterized the market over recent years is also clearly present in the current pipeline, with a strong presence of novel, targeted products.

Scope

  • The MM market landscape has undergone significant change over the past two decades.
  • Which classes of drug have emerged to dominate the market?
  • What survival benefits have these drugs produced?
  • How do the leading marketed therapies compare clinically?
  • The pipeline contains a range of molecule types and molecular targets not present in the current market, including a strong focus on therapies targeting common oncogenic pathways, such as the Phosphoinositide 3-Kinase/Protein Kinase B (PI3K/Akt) pathway.
  • Which molecular targets appear most frequently in the pipeline?
  • How will the new therapies be positioned in the treatment of MM?
  • How have selected late-stage pipeline therapies performed in clinical trials?
  • MM clinical trials have an overall attrition rate of 78%.
  • What are the failure rates for individual Phases of clinical development?
  • How do MM clinical trial characteristics, including failure rate, duration, and size compare against oncology and industry averages?
  • The MM market is forecast to rise from a value of $7.3 billion in 2014 to $8.9 billion in 2021, at a CAGR of 2.9% across the eight major markets assessed.
  • How much of a role will disease prevalence and new product approvals play in market growth?
  • Will generic competition have a significant impact on the market over the forecast period?
  • There have been 39 licensing deals and 22 co-development deals pertaining to MM products since 2006.
  • Which territories show the most deal activity?
  • What were the trends in deal completion by product stage of development?
  • What were the conditions of the key licensing or co-development deals to take place in MM?

Reasons to buy

  • Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in MM.
  • Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies and a heatmap directly comparing safety and efficacy data.
  • Analyze the MM pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
  • Predict growth in market size in eight major markets, with in-depth market forecasting from 2014-2021. The forecasts will provide an understanding of how epidemiology trends, new drug entry, and patent expirations will influence market value.
  • Identify commercial opportunities in the MM deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Etiology
  • 2.3. Pathophysiology
  • 2.4. Symptoms
  • 2.5. Diagnosis and Classification
  • 2.6. Epidemiology
  • 2.7. Prognosis and Disease Staging
  • 2.8. Treatment Options
    • 2.8.1. Treatment Algorithm
    • 2.8.2. Initial Therapy for Newly Diagnosed Symptomatic Disease
    • 2.8.3. Maintenance Therapy
    • 2.8.4. Therapy for Relapsed or Refractory Myeloma

3. Marketed Products

  • 3.1. Overview
  • 3.2. Immunomodulatory Agents
    • 3.2.1. Thalomid (thalidomide) - Celgene
    • 3.2.2. Revlimid (lenalidomide) - Celgene
    • 3.2.3. Pomalyst (pomalidomide) - Celgene
  • 3.3. Proteasome Inhibitors
    • 3.3.1. Velcade (bortezomib) - Millennium Pharmaceuticals/Takeda
    • 3.3.2. Kyprolis (carfilzomib) - Onyx
  • 3.4. Histone Deacetylase Inhibitors
    • 3.4.1. Farydak (panobinostat) - Novartis
  • 3.5. Chemotherapy
    • 3.5.1. Doxil (doxorubicin HCl liposome injection) - Janssen
  • 3.6. Comparative Efficacy and Safety of Marketed Products

4. Pipeline Products

  • 4.1. Overall Pipeline
  • 4.2. Pipeline Analysis by Molecular Target
  • 4.3. Clinical Trials
    • 4.3.1. Failure Rate
    • 4.3.2. Patient Enrolment and Clinical Trial Size
    • 4.3.3. Duration
  • 4.4. Competitive Clinical Trials Metrics Analysis
  • 4.5. Promising Drug Candidates in the Pipeline
    • 4.5.1. Ixazomib Citrate - Millennium Pharmaceuticals
    • 4.5.2. Zolinza (vorinostat) - Merck
    • 4.5.3. ARRY-520(filanesib) - Array Biopharma
    • 4.5.4. Aplidin (plitidepsin) - PharmaMar
    • 4.5.5. Elotuzumab - AbbVie and Bristol Myers Squibb
    • 4.5.6. Daratumumab - Johnson & Johnson
  • 4.6. Heat Map for Pipeline Products

5. Market Forecast to 2021

  • 5.1. Geographical Markets
  • 5.2. Global Market
  • 5.3. North America
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. Top Five EU Markets
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Japan
    • 5.5.1. Treatment Usage Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Size
  • 5.6. Drivers and Barriers for the Disease Market
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Licensing Deals
    • 6.1.1. Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab
    • 6.1.2. Genentech Enters into Licensing Agreement with Seattle Genetics - Now Terminated
    • 6.1.3. OncoPep Enters into Licensing Agreement with Dana-Farber Cancer Institute for Cancer Vaccine Technology
    • 6.1.4. PharmaMar Enters into Licensing Agreement with Chugai for Aplidin
    • 6.1.5. Onyx Enters into Licensing Agreement with Ono Pharma for Kyprolis and Oprozomib
  • 6.2. Co-development Deals
    • 6.2.1. Celgene Enters into Co-development Agreement with MedImmune
    • 6.2.2. Acetylon Enters into Co-development Agreement with Leukemia & Lymphoma Society
    • 6.2.3. Boehringer Ingelheim Enters into Collaboration Agreement with Micromet
    • 6.2.4. Multiple Myeloma Research Foundation Enters into Co-development Agreement with Onyx
    • 6.2.5. Dana-Farber Cancer Institute Enters into Agreement with MannKind
    • 6.2.6. Nordic Nanovector Enters into Co-development Agreement with Affibody

7. Appendix

  • 7.1. All Pipeline Drugs by Phase of Development
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. IND/CTA-filed
    • 7.1.4. Phase I
    • 7.1.5. Phase II
    • 7.1.6. Phase III
    • 7.1.7. Pre-registration
  • 7.2. Market Forecasts to 2021
    • 7.2.1. Global
    • 7.2.2. US
    • 7.2.3. Canada
    • 7.2.4. UK
    • 7.2.5. France
    • 7.2.6. Germany
    • 7.2.7. Italy
    • 7.2.8. Spain
    • 7.2.9. Japan
  • 7.3. Bibliography
  • 7.4. Abbreviations
  • 7.5. Research Methodology
    • 7.5.1. Secondary Research
    • 7.5.2. Marketed Product Profiles
    • 7.5.3. Late-Stage Pipeline Candidates
    • 7.5.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 7.5.5. Forecasting Model
    • 7.5.6. Deals Data Analysis
  • 7.6. Expert Panel Validation
  • 7.7. Contact Us
  • 7.8. Disclaimer

List of Tables

  • Table 1: Multiple Myeloma Therapeutics Market, Global, Initial Screening in Suspected Myeloma Patients
  • Table 2: Multiple Myeloma Therapeutics Market, Global, Diagnostic Criteria for MGUS, Asymptomatic Myeloma and Symptomatic Myeloma
  • Table 3: Multiple Myeloma Therapeutics Market, Global, Myeloma-Related Organ or Tissue Impairment
  • Table 4: Multiple Myeloma Therapeutics Market, Global, Disease Staging, Durie-Salmon Staging System
  • Table 5: Multiple Myeloma Therapeutics Market, Global, Prognostic Factors
  • Table 6: Multiple Myeloma Therapeutics Market, Global, Prognostic Factors
  • Table 7: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Discovery, 2015
  • Table 8: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Preclinical, 2015
  • Table 9: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2015
  • Table 10: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Phase I, 2015
  • Table 11: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Phase II, 2015
  • Table 12: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Phase III, 2015
  • Table 13: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Pre-registration, 2015
  • Table 14: Multiple Myeloma Therapeutics Market, Global, Market Forecast, 2014-2021
  • Table 15: Multiple Myeloma Therapeutics Market, US, Market Forecast, 2014-2021
  • Table 16: Multiple Myeloma Therapeutics Market, Canada, Market Forecast, 2014-2021
  • Table 17: Multiple Myeloma Therapeutics Market, UK, Market Forecast, 2014-2021
  • Table 18: Multiple Myeloma Therapeutics Market, France, Market Forecast, 2014-2021
  • Table 19: Multiple Myeloma Therapeutics Market, Germany, Market Forecast, 2014-2021
  • Table 20: Multiple Myeloma Therapeutics Market, Italy, Market Forecast, 2014-2021
  • Table 21: Multiple Myeloma Therapeutics Market, Spain, Market Forecast, 2014-2021
  • Table 22: Multiple Myeloma Therapeutics Market, Japan, Market Forecast, 2014-2021

List of Figures

  • Figure 1: Multiple Myeloma Therapeutics Market, Global, Average Number of New Cases per Year and Age Specific Incidence Rates, UK, 2009-2011
  • Figure 2: Multiple Myeloma Therapeutics Market, Global, Treatment Algorithm for Myeloma
  • Figure 3: Multiple Myeloma Therapeutics Market, Global, Heat Map for Initial Treatment - Efficacy
  • Figure 4: Multiple Myeloma Therapeutics Market, Global, Heat Map for Initial Treatment - Safety
  • Figure 5: Multiple Myeloma Therapeutics Market, Global, Heat Map for Maintenance Treatment
  • Figure 6: Multiple Myeloma Therapeutics Market, Global, Heat Map for Relapsed or Refractory Multiple Myeloma - Efficacy
  • Figure 7: Multiple Myeloma Therapeutics Market, Global, Heat Map for Relapsed or Refractory Multiple Myeloma - Safety
  • Figure 8: Multiple Myeloma Therapeutics Market, Global, Overview of Pipeline Products
  • Figure 9: Multiple Myeloma Therapeutics Market, Global, Target Families in the Pipeline
  • Figure 10: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Overall Attrition Rate and Failure Rate by Phase, 2006-2015
  • Figure 11: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Overall Attrition Rate and Failure Rate by Phase and Molecule Type, 2006-2015
  • Figure 12: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Attrition Rate and Failure Rate by Phase and Molecular Target, 2006-2015
  • Figure 13: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type, 2006-2015
  • Figure 14: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecule Type, 2006-2015
  • Figure 15: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Product by Molecular Target, 2006-2015
  • Figure 16: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecular Target, 2006-2015
  • Figure 17: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type, 2006-2015
  • Figure 18: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target, 2006-2015
  • Figure 19: Multiple Myeloma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
  • Figure 20: Multiple Myeloma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Figure 21: Multiple Myeloma Therapeutics Market, Global, Ixazomib Citrate Market Forecast, 2020-2021
  • Figure 22: Multiple Myeloma Therapeutics Market, Global, Zolinza Market Forecast, 2019-2021
  • Figure 23: Multiple Myeloma Therapeutics Market, Global, ARY-520 Market Forecast, 2020-2021
  • Figure 24: Multiple Myeloma Therapeutics Market, Global, Elotuzumab Market Forecast, 2017-2021
  • Figure 25: Multiple Myeloma Therapeutics Market, Global, Daratumumab Market Forecast, 2017-2021
  • Figure 26 : Multiple Myeloma Therapeutics Market, Global, Pipeline Heat Map, 2015
  • Figure 27: Multiple Myeloma Therapeutics Market, Global, Treatment Patterns ('000) and Market Size ($bn), 2014-2021
  • Figure 28: Multiple Myeloma Therapeutics Market, North America, Treatment Patterns, 2014-2021
  • Figure 29: Multiple Myeloma Therapeutics Market, North America, Annual Cost of Therapy ($), 2014-2021
  • Figure 30: Multiple Myeloma Therapeutics Market, North America, Market Size, 2014-2021
  • Figure 31: Multiple Myeloma Therapeutics Market, EU, Treatment Patterns, 2014-2021
  • Figure 32: Multiple Myeloma Therapeutics Market, EU, Annual Cost of Therapy ($), 2014-2021
  • Figure 33: Multiple Myeloma Therapeutics Market, EU, Market Size, 2014-2021
  • Figure 34: Multiple Myeloma Market, Japan, Treatment Usage Patterns ('000), 2014-2021
  • Figure 35: Multiple Myeloma Market, Japan, Annual Cost of Therapy ($), 2014-2021
  • Figure 36: Multiple Myeloma Therapeutics Market, Japan, Market Size ($m), 2014-2021
  • Figure 37: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Region, 2006-2015
  • Figure 38: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Deal Value ($m), 2006-2015
  • Figure 39: Multiple Myeloma Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006-2015
  • Figure 40: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2015
  • Figure 41: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2015
  • Figure 42: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Molecular Target, 2006-2015
  • Figure 43: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Region, 2006-2015
  • Figure 44: Multiple Myeloma Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, 2006-2015
  • Figure 45: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Stage of Development, 2006-2015
  • Figure 46: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2006-2015
  • Figure 47: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2015
Back to Top